201. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
- Author
-
Hofland J, Feelders RA, van der Wal R, Kerstens MN, Haak HR, de Herder WW, and de Jong FH
- Subjects
- Adrenal Cortex Function Tests standards, Adrenal Cortex Neoplasms blood, Adrenal Cortex Neoplasms pathology, Adrenocortical Adenoma blood, Adrenocortical Adenoma diagnosis, Adrenocortical Carcinoma blood, Adrenocortical Carcinoma pathology, Adult, Aged, Diagnosis, Differential, Diagnostic Techniques, Endocrine standards, Disease Progression, Female, Humans, Inhibins blood, Male, Middle Aged, Osmolar Concentration, Protein Precursors blood, Reference Values, Young Adult, Adrenal Cortex Neoplasms diagnosis, Adrenocortical Carcinoma diagnosis, Biomarkers, Tumor blood, Inhibins physiology, Protein Precursors physiology
- Abstract
Objective: The insufficient diagnostic accuracy for differentiation between benign and malignant adrenocortical disease and lack of sensitive markers reflecting tumor load emphasize the need for novel biomarkers for diagnosis and follow-up of adrenocortical carcinoma (ACC)., Design: Since the inhibin α-subunit is expressed within the adrenal cortex, the role of serum inhibin pro-αC as a tumor marker for ACC was studied in patients., Methods: Regulation of adrenal pro-αC secretion was investigated by adrenocortical function tests. Serum inhibin pro-αC levels were measured in controls (n=181) and patients with adrenocortical hyperplasia (n=45), adrenocortical adenoma (ADA, n=32), ACC (n=32), or non-cortical tumors (n=12). Steroid hormone, ACTH, and inhibin A and B levels were also estimated in patient subsets., Results: Serum inhibin pro-αC levels increased by 16% after stimulation with ACTH (P=0.043). ACC patients had higher serum inhibin pro-αC levels than controls (medians 733 vs 307 ng/l, P<0.0001) and patients with adrenocortical hyperplasia, ADA, or non-adrenocortical adrenal tumors (148, 208, and 131 ng/l, respectively, P=0.0003). Inhibin pro-αC measurement in ACC patients had a sensitivity of 59% and specificity of 84% for differentiation from ADA patients. Receiver operating characteristic analysis displayed areas under the curve of 0.87 for ACC vs controls and 0.81 for ACC vs ADA (P<0.0001). Surgery or mitotane therapy was followed by a decrease of inhibin pro-αC levels in 10/10 ACC patients tested during follow-up (P=0.0065)., Conclusions: Inhibin pro-αC is produced by the adrenal gland. Differentiation between ADA and ACC by serum inhibin pro-αC is limited, but its levels may constitute a novel tumor marker for ACC.
- Published
- 2012
- Full Text
- View/download PDF